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DEVICE FOR TISSUE REPAIR 
FIELD OF THE INVENTION 
The present invention relates to a hydrogel based device for 
use as tissue repair. 
BACKGROUND OF THE INVENTION 
2 
operations are of the order of 40-50%, which is much higher 
than the rate with autologous and allogenic ligaments. 
As an alternative to non-biodegradable artificial ligaments, 
research efforts are being carried out to develop tissue engi-
neered (TE) ligaments for which a biodegradable scaffold 
first replaces the native ligament and is progressively replaced 
by a new reconstructed living tissue. Several systems have 
recently been designed using silk, collagen or poly lactic acid 
biodegradable fibers (Freeman J. W. et al. Journal ofBiome-
10 chanics, 2010, doi: 10.1016/j.biomech. 2010.10.043). Never-
theless, the management of cell sourcing as well as the control 
of scaffold degradation while ensuring proper mechanical 
properties remain unsolved issues that still need to be 
addressed before clinical use. 
Hundreds of thousands of anterior cruciate ligaments 
(ACL) are tom every year and this trend has been increasing 
with the rise of participation in sports in the general popula-
tion and in particular in females and older participants. For 
young and/or athletic active individuals the standard care is 
based on ligament reconstruction. Several replacement tis- 15 
sues can be envisaged using either grafts (auto, allo and xeno) 
Most of the patents deal with the methods of attachment or 
fixation design to attach an artificial ligament to the bones of 
a joint. Recent examples are given below. 
FR 2 700 111 relates to an artificial ligament consisting of 
a fixed section and a moving sleeve which form two separate 
or artificial materials. Xenografts, ligaments from other ani-
mals, and allografts from cadaveric human tissue are possi-
bilities that overcome the need to autologous tissues and 
avoid the risk of donor-site morbidity. However, their use 
poses several issues including risks of disease transmission, 
graft rejection and inflammation. Moreover, in the case of 
allografts, the supply is so small that the market demand can 
never be met from this source. Autograft tissues extracted 
from the patellar tendon, quadriceps tendon-patellar bone or 
the hamstring tendons are currently the most common 
sources of grafts for ACL reconstruction. Yet this therapy 
relies on the extraction of healthy tissue which implies risks 
20 ligaments of the same or different lengths, joined together so 
that they can slide relative to one another. The two ligaments 
can be made from plaited, woven or knitted fibres of the same 
or different materials, with their ends joined together by a 
thermo-shrink material or a supple adhesive. The outer liga-
25 ment can be made with sections of reduced resistance which 
allow its length to be varied. The ligaments can be made from 
Dacron® (RTM) or other synthetic fibres, or from natural 
cellulose fibres which are treated to make them biocompat-
ible. of donor-site morbidity, an initial low strength, a high prob-
ability of rupture at the initial stages and a long and painful 30 
recovery period. The use of artificial prosthetic ligaments as 
an alternative to autografts could bring substantial improve-
ments in the existing reconstruction therapies. 
Several prosthetic devices for ACL replacement have been 
made over the past thirty years using a wide range of materi- 35 
als. The materials which have been considered for these 
devices including polyester (Stryker Dacron® ligament pros-
thesis, Leeds-Keio), polytetrafluoroethylene and fluoropoly-
mers (Gore-Tex®), carbon fibers, polyethylene, nylon and 
polystyrene. However none of these artificial ligaments have 40 
demonstrated positive long term results in vivo. Failures of 
previous devices mostly originate from mechanical failures 
or from a lack of biocompatibility. Mechanical failures 
include i) rupture caused by wear, fatigue or severe loading in 
the knee and ii) laxity in the joint after creep of the prosthetic 45 
ligament or loosening of the fixation element in the bone. 
Biocompatibility issues primarily manifest as immunogenic 
particulation leading to chronic synovitis. Due to high inci-
dence of such problems, most if not all the previous artificial 
ligaments have been withdrawn from the commercial market. 50 
For example, no such devices are currently approved for 
clinical use by the Food and Drug Administration of the 
United States of America (FDA). 
Over the last decades, statistics have been collected that 
confirm the poor long term efficacy of existing artificial liga- 55 
ments. A study of 855 artificial cruciate ligaments over a 
15-yearperiod found that there was 40-78% failure rate (Fu F. 
H. et al. American Journal of Sports Medicine, 2000, 28(1 ), 
124-130). Another report found that around 80% of knees 
which had been reconstructed using Dacron prosthetic liga- 60 
ments had developed significant osteoarthritic symptoms at a 
9 year follow up (Fu F. H. cited above). Similarly, a study of 
268 patients revealed that Gore-Tex® anterior cruciate liga-
ment prosthesis yielded a failure rate of 42% with case of 
effusions, rupture and strong loosening (George M. S. et al, 65 
American Journal of Sports Medicine, 2006, 34(12), 2026-
2037). Overall, complication rates for artificial ligament 
US 2003/114929 discloses a prosthetic ligament including 
a cord ofthermotropic liquid crystal filaments. Preferably the 
cord is a string or thin rope made by several strands braided, 
twisted, or woven together. Strands are, preferably, made of a 
multi-filament thread. 
U.S. Pat. No. 5,800,543 relates to an artificial ligament 
device comprising a plurality of tows ofbiocompatible mate-
rial (for example polyester) secured side-by-side in a flat 
elongate array by braiding, the tows being looped back at one 
end of the device to form an eye, the flat lengths adjoining the 
eye being secured to each other side-by-side by stitching, the 
tows around the eye being grouped together and whipped, and 
lashing being applied around a base of the eye. 
WO 2009/047767 provides a ligament prosthesis having a 
first end and a second end, comprising a first load bearing 
element and a second load bearing element, the first and 
second load bearing elements differing in one or more 
mechanical properties and being arranged in the prosthesis in 
series. The load bearing elements may be made from an alloy 
and, in order to protect nearby organs and tissues from abra-
sion from the prosthesis and vice versa, may be contained in 
a sleeve made from biodegradable polymers such as poligle-
caprone, polyglycolic acid, polylactic acid, polydioxanone, 
or co-polymers of the aforementioned polymers. 
WO 2009/11307 6 provides a ligament prosthesis having an 
undeployed configuration and a deployed configuration. The 
prosthesis has a resistance to tension in the undeployed con-
figuration that is less than its resistance to tension in the 
deployed configuration. In the deployed configuration, the 
prosthesis is capable of twisting and bending. In one embodi-
ment, the prosthesis has a meshwork of filaments woven, 
knitted or braided into a slender cylinder. The prosthesis may 
be used to replace an anterior or posterior cruciate ligament. 
WO 98/22046 discloses a "free strand" ligament that is 
naturally self-convoluted between the two ends of the intra-
articular median part. 
With the foregoing disadvantages of the prior art in mind, 
it appears that there is a need for a device which i) is biocom-
US 9,180,000 B2 
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patible on the short and long term, meaning after years of 
implantation in vivo, ii) reproduces closely the non-linear 
elastic mechanical behaviour of native ligaments and tendons 
including the stiffness and the toe-region, iii) ensures ultimate 
tensile stress (strength) and ultimate tensile strain that are safe 
with respect to the patient's activity. Polymer hydrogels con-
stitute relevant materials in that respect. 
Hydrogels, also called aquagels, are hydrophilic polymer 
networks that can absorb water and swell without dissolving 
4 
at least temporarily. Depending on the physico-chemical 
properties of these networks, levels of water absorption can 
vary greatly from about 10% to thousand times their dry 
weight. An important characteristic ofhydrogels is that they 
can possess a water content and a molecular structure very 
similar to those of living tissues. These features confer them 
biocompatibility, lubricity, rubbery elasticity and possibly 
biodegradability, which are of interest for biomedical appli-
cations and more particularly tissue replacement. Examples 
ofhydrogel forming polymers that are relevant for biomedi-
in a patient at the location of respectively a ligament or a 
tendon and which is made of biocompatible hydrogel and 
reproduces closely the tensile mechanical response of native 
ligaments or tendon with values of ultimate tensile stress and 
ultimate tensile strain that are appropriate for ligament or 
tendon repair. It can be placed in the patient using minimally 
invasive techniques. Unlike autograft techniques, this device 
does not necessitate the sacrifice of healthy tendons or liga-
ments from the patient. 
10 Thus an object of the present invention is a biocompatible 
device in the form of an elongated body comprising at least a 
flexible median part between two end parts, said body having 
a fibrous structure formed from biocompatible hydrogel 
15 fibers, said hydro gel fibers being assembled to form the body 
of the device. 
A further object of the present invention is a biocompatible 
device in the form of an elongated body comprising a flexible 
median part between two end parts showing a different tensile cal applications are polyvinyl alcohol, polyethylene-glycol, 
polysaccharides, polylactic acids and their copolymers 
U.S. Pat. No. 5,981,826 provides a poly(vinyl alcohol) 
hydrogel construct having a wide range of mechanical 
strengths for use as a human tissue replacement. It may be 
especially useful in surgical and other medical applications as 
20 stiffness from that of the median part, said body having a 
fibrous structure formed from biocompatible hydrogel form-
ing fibers, said hydrogel forming fibers forming the body of 
the device. 
an artificial material for replacing and reconstructing soft 25 
tissues in humans and other mammals. Soft tissue body parts 
which can be replaced or reconstructed by the hydrogel 
include vascular grafts, heart valves, esophageal tissue, skin, 
corneal tissue, cartilage, meniscus, and tendon. However, the 
reported tensile modulus of elasticity for the so-prepared 
30 
material is less than 1 MPa, which is too low as compared to 
the ultimate tensile stress ofligaments and tendons, which is 
greater than 100 MPa. 
The words "terminal end parts" can also be used in place of 
"end parts" but the language "end parts" is preferred. 
The words "hydrogel fibers", can also be used in place of 
"hydrogel forming fibers" but the language "hydrogel form-
ing fibers" is preferred. The word "forming" can also be 
inserted in the terms "hydrogel matrix", "hydrogel poly-
mers". 
The words "continuous" and "threads" are synonymous. 
According to the invention, the word "biocompatible" 
means that the hydrogel and the device elicit little or no 
immune response in a given organism, or is able to integrate 
with the tissue. 
According to the invention, the word "fibrous" means that 
the body of the device contains at least 1 % in weight of 
products of fibrous nature. Preferably, the body of the device 
contains at least 10% in weight of products of fibrous nature 
According to the invention the flexible median part repro-
duces the behavior of the natural ligament or tendon whereas 
at least one end part is designed to be fixed on a bone. 
According to the invention, the body may be formed by any 
W0/2006/102756 relates to a hydrogel exhibiting aniso-
tropic properties which is poly(vinyl alcohol) produced by 
preparing a solution of poly(vinyl alcohol) with a pre-se- 35 
lected concentration, thermally cycling the solution by freez-
ing and thawing, stretching the hydrogel and thermally 
cycling the hydrogel at least one more time. Said anisotropic 
hydrogel is used for soft tissue replacement selected from 
vascular vessels, coronary arteries, heart valve leaflets, heart 40 
valve stent, cartilage, ligaments and skin. However, the ulti-
mate tensile stress forthe so-prepared materials do not exceed 
0.4 MPa, which is too low as compared to the ultimate tensile 
stress ofligaments and tendons, estimated in the range 30-50 
MP a. 
W0/2001/017574 discloses a hydrogel intended for ortho-
pedic applications wherein the tissue is selected from the 
group consisting of bone, cartilage, meniscus, bursa, synovial 
membranes, tendons, ligaments, muscle and vertebral disks. 
Like for W0/2006/102756, the ultimate tensile stress for the 
preferred material is about 8 MPa, which is too low for the 50 
replacement of most ligaments and tendons. 
45 techniques known from the one skilled in the art, for example 
by simple assembly of the fibers keeping them individual, by 
assembly of the fibers into threads or strands, by braiding, by 
knitting or by weaving. 
JP4141178 discloses an artificial tendon and an artificial 
ligament consisting of polyvinyl alcohol fiber with a tensile 
strength of 12 g/d or larger and a tensile breaking elongation 
According to the invention, the device is advantageously 
an artificial ligament used for repairing any ligament in ani-
mals, in particular non human mammals or humans. Liga-
ments which may be repaired may be selected from the fol-
lowings: head and neck ligaments (cricothyroid ligament, 
periodontal ligament, suspensory ligament of the lens), wrist 
of 6% or smaller which is much less than the devices of the 55 ligaments (palmar radiocarpal ligament, dorsal radiocarpal 
ligament, ulnar collateral ligament, radial collateral liga-present invention 
Anon-biodegradable device that can be installed in-vivo to 
repair a ligament or tendon, that is biocompatible and that 
reproduces closely the mechanical properties of native liga-
ments and tendons as well as ensures the appropriate values of 
tensile strength and ultimate tensile strain required for liga-
ment or tendon replacement is needed. 
DESCRIPTION OF THE INVENTION 
The inventors propose a novel type of device, in particular 
an artificial ligament or tendon which can be placed and fixed 
ment), shoulder ligament (rotator cuff), knee ligament (ante-
rior cruciate ligament (ACL), lateral collateral ligament 
(LCL), posterior cruciate ligament (PCL), medial collateral 
60 ligament (MCL), cranial cruciate ligament (CrCL)-quadru-
ped equivalent of ACL, caudal cruciate ligament (CaCL)-
quadruped equivalent of PCL, patellar ligament). 
65 
Anterior cruciate ligament (ACL) is the most likely liga-
ment to be replaced by the device of the invention. 
A further object of the present invention is a device wherein 
the two end parts show a higher tensile stiffness than that of 
the flexible median part. 
US 9,180,000 B2 
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Another object of the present invention is a device wherein 
the two end parts show a higher bending stiffness than that of 
the flexible median part. 
A further object of the present invention is a device wherein 
the median part shows an ultimate tensile strain greater than 
6%, advantageously from 6 to 100%, more advantageously 
from 10 to 80%. 
A further object of the present invention is a device wherein 
the two end parts show a tensile stiffness that is from 10% to 
100 times in particular 10%, 50%, 2 or 5 times higher, than 
that of the flexible median part. 
A further object of the present invention is a device wherein 
the end parts are placed adjacently to each of the ends of the 
median part and are made of swellable, porous and braided, 
twisted, woven or knitted sections. The end parts sections 
may be permeable. 
A further object of the present invention is a device wherein 
the swelling of the end parts is less than 40%, preferably less 
than 20% in weight and the porosity is greater than 1 %. 
The swelling of the device is measured according to stan-
dard procedures. 
Swelling is the property of a device whereby the volume 
increases upon exposure to water. 
6 
A device according to the invention wherein the median 
part shows in the 10 to 15% strain range a tensile stiffness 
comprised from about 10 to 500 N/%, preferably from about 
20 to about 300 N/%. 
A device according to the invention can advantageously 
show an ultimate tensile load greater than 30 N advanta-
geously comprised between 300 and 4000N 
A device according to the invention can advantageously 
show a bending stiffness from 10 to 100 MPa. 
10 A device according to the invention wherein the median 
part shows a flexural modulus from 0.1 to 200 MPa advanta-
geously comprised between 1 and 100 MPa. 
According to the invention, the device is advantageously 
15 made of continuous fibers. The threads used to make the 
device can also be continuous. 
By continuous fibers it is meant that the fibers are pro-
longed and span from one end of the device to the other end 
without interruption. Preferably, a type of fiber that covers the 
20 entire dimension of a part without a break or interruption is 
used. 
In an advantageous embodiment of the invention, the cen-
tral core of the device is made of a bundle of parallel or 
twisted threads. 
Porosity is the property of a device whereby open spaces or 25 
pores exist without polymeric material. Cells can migrate into 
the spaces or pores contained in the device. Porosity is defined 
In a preferred embodiment of the invention, a device 
according to the invention has end parts that are made of 
tubular braided, twisted, woven or knitted sections that con-
tain at least one osseointegration promoting substance and/or 
has holes at each end of the tubular section or on the side of it 
as the fraction of the volume of open spaces or pores over the 
total volume. 
In some of the devices according to the invention, the 
flexible median part has a non linear elasticity. 
30 to allow injection of materials into the space inside the tube. 
The invention concerns more particularly a device having a 
median part whose tension stress-strain curve shows a low 
stiffness region at the lowest levels of tensile strain and a 35 
higher stiffness region at greater levels of strain. 
A device according to the invention has end parts that are 
coated or impregnated with one or several osseointegration-
promoting substances, preferably calcium phosphate and/or 
calcium sulfate. 
A device according to the invention is characterized in that 
at least one of the end parts is filled with a substance, prefer-
ably bone mulch or bone cement or a mineral filler preferably 
a bioactive glass or hydroxyapatite. 
In some of the devices according to the invention, the 
flexible median part has a linear elasticity. 
In an advantageous embodiment, the tensile strength and 
the ultimate tensile strain of the device defined above are 40 
The term bioactive glass is well known in the art. These 
materials usually contain Ca-phosphates and or Ca-sulphates. 
CaO, P2 0 5 , Si02 and Na20 are typical constituents for bio 
elements. 
measured after equilibration in water or bodily liquids, until 
weight is stable, typically a few hours at 20° C. The same 
conditions also apply to the measure of the ultimate tensile 
load, tensile stiffness, tensile modulus and flexural modulus. 
The device according to the invention shows a tensile 
strength between 10 and 200 MPa, advantageously between 
15 and 50 MPa (corresponding to an ultimate load between 
1100 and 4000N for a ligament with a diameter of 1 cm) and 
an ultimate tensile strain between 10 and 100%, advanta-
geously 15-80%. 
In an advantageous embodiment, the device according to 
the invention shows an ultimate tensile load between 30 and 
60000N, advantageously comprised between 300 and 4000N 
and an ultimate tensile strain comprised between 10 and 
100%, advantageously between 15 and 80%. 
Another aspect of the invention concerns a device as 
defined above showing a tensile strength greater than 10 MPa, 
advantageously comprised from 15 to 50 MPa. 
A device according to the invention can advantageously 
show in the 0 to 5% strain range a tensile modulus of 1 to 500 
MPa in particular 1 to 10, 10 to 40, 40 to 100, 100 to 150, 150 
to 300, 300 to 500 MPa. 
A device according to the invention can also advanta-
geously show in the 10 to 15%. strain range a tensile modulus 
1 to 500 MPa in particular 1 to 10, 10 to 40, 40 to 100, 100 to 
150, 150 to 300, 300 to 500 MPa 
Examples of commercially available materials contain: 
46.1 mo!% Si02 , 26.9 mo!% CaO, 24.4 mo!% Na2 0 and 
45 2.5 mo!% P 2 0 5 . Bio glass 60 mo!% Si02 , 36 mo!% CaO and 
4mol %P20 5 . 
50 
70 mo! % Si02 , 30 mo! % CaO. 
Other biocompatible materials like porcelain, alumina, zir-
conia can also be used. 
In a preferred embodiment of the invention, device accord-
ing to the invention, the hydrogel forming fibers are made of 
polyvinyl alcohol. 
In a preferred embodiment of the invention, the hydrogel 
forming fibers are made of polyvinyl alcohol having a water 
55 absorption higher than 10% and preferably comprised 
between 10 and 80% in weight. 
According to the invention any biocompatible hydrogel 
known from the one skilled in the art may be used if the 
moisture content is comprised between 10 and 80%. A suit-
60 able hydro gel is, for example, the PVA hydro gels disclosed in 
U.S. Pat. No. 5,981,826, or sold by Salumedica LLC. Com-
mercial hydrogel forming fibers can be used like PVA fibers 
Solvron® sold by Nitivy Company Ltd. 
Preferably, the hydrogel forming fibers are made of poly-
65 vinyl alcohol fibers having a linear mass density of 8· 10-5 to 
2500 deniers preferably 45 deniers and a tensile strength 
greater than 10 g/d preferably 44 g/d. 
US 9,180,000 B2 
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Fibers having a diameter of 0.1 to 1 µm made by electro-
spinning or fibers having a diameter from 1 to 500 µm made 
by conventional methods can be used. It is well in the knowl-
edge of the one skilled in the art to adjust the number of fibers 
or threads to the size and density of the fibers. For instance, if 5 
very fine fibers like those obtained by electrospinning (typi-
cally on the micro or nano scale) are used the skilled artisan 
will use many more fibers to make the device according to the 
invention. 
In an advantageous embodiment according to the inven- 10 
tion, the fibrous structure may also contain other type of 
biocompatible fibers assembled with the hydrogel fibers, for 
example biocompatible carbon fibers or metal fibers like tita-
nium and titanium alloy fibers or polymeric fibers selected 15 
from the group consisting of polyethylene (PE), polypropy-
lene (PP), polyamides (PA), polycarbonates (PC), polyure-
thanes (PU), polyurethane urea, polyesters like polyethylene 
terephtalate (PET), polyfluoropolymers like polytetrafluoro-
ethylene (PTFE), polyacrylates like polymethyl methacrylate 20 
(PMMA), polyethylene glycol (PEG), poly-L-lactic acid 
(PLLA), poly-G-lactic acid (PGLA), poly-caprolactone 
(PCL), polyglycolide, polysaccharides like cellulose, hyalu-
ronic acid, proteins like elastin, silk, collagen and from blends 
8 
Then in an advantageous embodiment of the invention, the 
anchoring system may be the hydrogel coated or embedded 
end parts of the device themselves. 
It is to be noted that the terms embedded and entrapped are 
usually synonymous. 
Where coating by a hydrogel or embedding in a hydrogel 
matrix is performed on the fibers or strands, then it is per-
formed prior to assembly of the body. Said matrix or coating 
plays several roles: 
i) It better redeploys the efforts between fibers 
ii) It lubricates the contact between the device and sur-
rounding tissues thus diminishing the risks of inflamma-
tion and of failure by wear, 
iii) It provides additional stiffness to the end parts in order 
to reduce deformation in the bone tunnels and favor 
adhesion with bone. 
iv) According to the properties of the hydrogel, it is used 
either to prevent cellular adhesion on the median part of 
the body or to reinforce the bone-device interface and 
accelerates the osseous integration of the end parts. 
The device may have any form suitable for repairing the 
corresponding natural part. It is generally elongated in shape 
and the anchoring system at at least one end of the device is 
adapted for attachment to a musculo-skeletal tissue such as 
or copolymers obtained with polymers from this group. 25 bone. 
More preferably, the fibrous structure may also contain 
other types ofbiocompatible fibers assembled with the hydro-
gel fibers, for example fibers made in one or several of the 
following polymers can be used: Polyethylene (PE), Poly-L-
lactic acid (PLLA), Poly-G-lactic acid (PGLA), Poly-capro- 30 
lactone (PCL), Silk, Polyesters, Polyethylene terephtalate 
(PET), Polytetrafluoroethylene (PTFE), PLGA, Ti wires 
fibers assembled with the hydrogel forming fibers. 
A device according to the invention is characterized in that 35 
the body is partly or totally coated or entrapped in a hydro gel 
matrix. 
According to the invention, the diameter of the device is 
similar to the one of the natural part to be repaired; for 
example in the case of an artificial ligament for repairing a 40 
human knee ligament the diameter of the device is between 2 
mm and 2 cm, advantageously comprised between 5 and 10 
mm. The length of the body is also similar to the one of the 
natural ligament. For the case of the human knee ligament, it 
is between 0.5 and 5 cm and the length of the whole ligament 45 
comprising the median part and the end parts is between 5 and 
25 cm, advantageously between 10 and 20 cm, more advan-
tageously is equal to about 15 cm. The choice of the diameter 
and of the length of the device is well in the hand of the one 
skilled in the art who may adapt said parameters to the type of 50 
ligament or tendon he wishes to repair. 
According to the invention, the device may further contain 
anchoring systems at least at one end part which may be any 
system known from the one skilled in the art, like for example 
a hook, a screw, a buckle, a bone anchor, an interference 55 
screw, a cross pin or a suture button. It may also be an eye 
spliced at said end of the device. 
In an advantageous embodiment according to the inven-
tion, either the fibers, or the assembly of fibers (threads, 
strands, braid, knit fabric or woven fabric) or the whole body 60 
or both of them or the three are entrapped in a hydro gel matrix 
or coated by a hydrogel, said hydrogel being the same or 
being different from the hydrogel used for the fibers. Said 
coating or matrix may contain mineral fillers imparting better 
anchoring on the bone like calcium phosphates (hydroxyapa- 65 
tite and the like) or may be swollen by water in situ in order to 
have better anchoring on the bone. 
In an advantageous embodiment of the invention, the 
device has three parts: a central part and two extreme parts. In 
the case of a cruciate ligament the extreme parts are called 
respectively tibial and femoral part and the central part is 
called ligamentous part. 
In an advantageous embodiment according to the inven-
tion, the fibers may be assembled to threads, and the strands 
are strands of threads. The strands may be twisted in the 
opposite direction of the twist of the threads to gain a greater 
stiffness and cohesion of the structure. 
In another advantageous embodiment, the strands may sur-
round a hollow core. The obtained structure has several roles: 
i) The hollow core provides a lower resistance to bending 
and thus a greater flexibility to the central part. 
ii) The hollow core can be filled by a substance like bone 
cement or bone mulch or an appropriate fixation device 
like interference screws to better fix one or both of the 
extreme parts, tibial and femoral parts in the case of knee 
ligaments. 
In another advantageous embodiment of the invention, the 
fibers are oriented in a direction of loading of the prosthetic 
ligament. 
In another advantageous embodiment of the invention, the 
fibers may be assembled to threads, and the threads are ori-
ented in a direction ofloading of the prosthetic ligament. 
In another advantageous embodiment the assembly pattern 
can be different for each part. For example, where the fibers 
are assembled into strands, strands can be twisted in the 
central part and braided in the end-parts. 
The fibers themselves or the coating or both may contain at 
least one compound selected from the group consisting of 
growth factors, drugs like anti-inflammatory drugs or a min-
eral filler like calcium phosphates (hydroxyapatite and the 
like). 
In an advantageous embodiment, the stiffness of the device 
of the invention is comprised from about 10 to 500 N/%, 
preferably from about 20 to about 300 N/%. 
Typical devices for ACL replacement that can be prepared 
according to the present invention contain 16 polyvinyl alco-
hol strands that can be assembled parallel to the direction of 
loading or consist in 4 twisted ropes each consisting of 4 PVA 
strands twisted together. Another type of device is made of 22 
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PVA strands consisting in 4 braided PVA strands surrounded 
by 6 twisted ropes each consisting of3 PVA strands twisted 
together. Alternatively up to 27 UHMWPE threads can be 
substituted for some of the PVA strands. 
The annealing step can preferably be performed at a tern- 5 
perature comprised between 130 and 190° for 10 minutes to 
one hour. 
Practical intermediates materials for preparing devices 
according to the invention are disclosed thereafter. These 
intermediates are then treated to differentiate the end parts 10 
and the median part. The end parts and median part of the 
device can be treated separately by the methods disclosed 
herewith. 
1) 16 PVA (polyvinyl alcohol) strands assembled parallel 
to the direction ofloading. 
2) 16 PVA strands consisting of 4 twisted ropes each con-
sisting of 4 PVA strands twisted together. 
15 
10 
Cross-linking in step c) may be performed by any tech-
niques known in the art. Suitable techniques include applica-
tion of heat and/or irradiation like UV or ganmia rays and/or 
chemicals like dialdehydes in the case of PVA hydrogels 
and/or freezing/thawing or drying/rehydrating cycles. 
In a preferred embodiment of the process in the case where 
polyvinyl alcohol fibers are used, step c) comprises a physical 
cross-linking step selected from a series of freezing/thawing 
cycles and/or drying/rehydrating cycles and/or a chemical 
cross-linking step preferably using irradiation and/or a dial-
dehyde cross-linker preferably glutaraldehyde 
In a further embodiment of the process according to the 
invention, the assembly of fibers of step a) is performed 
around a rod to form a hollow 
In a third embodiment of the process according to the 
invention, it further comprises an annealing step of a part or 
the whole body of the device above the glass transition tem-
perature of the hydrogel forming polymer and below the 
dissociation temperature of the hydrogel network. In the case 
3) 22 PVA strands consisting of a Central core of 4 braided 
PVA strands surrounded by 6 twisted ropes each con-
sisting of3 PVA strands twisted together. 
4) Same as the preceding device with 27 UHMWPE 
threads together as a unit substituted for one of the PVA 
strands in the braided central core (21 PVA strands and 
20 of polyvinyl alcohol, the temperature of the said step is pref-
erably in the range between 100° C. to 200° C. Said annealing 
step may be performed directly on the fibers prior to step a) or 
before or after step c ). 
27 UHMWPE threads in total) 
5) 16 PVA strands assembled parallel to the direction of 25 
loading with annealing of the structure at 130° C. for 1 
hour. 
6) 16 PVA strands assembled parallel to the direction of 
loading with annealing of the structure at 160° C. for 1 
hour. 
7) 16 PVA strands assembled parallel to the direction of 
loading with annealing of the structure at 190° C. for 1 
hour. 
30 
8) 16 PVA strands assembled parallel to the direction of 
loading with annealing of the structure at 160° C. for 10 35 
minutes 
9) 16 PVA strands assembled parallel to the direction of 
loading with annealing of the structure at 190° C. for 10 
minutes 
10) 16 PVA strands assembled parallel to the direction of 40 
loading with coating by PVA hydro gel using the immer-
sion method and applying one freezing-thawing cycle. 
The device according to the invention may be prepared by 
any process known from the one skilled in the art. The process 
shall permit the modification of each part of the body sepa- 45 
rately. 
The process according to the invention the annealing step 
can also be performed at a temperature near the melting point 
of the hydro gel forming fibers, before or after step c) on a part 
or the whole body of the device 
In a preferred embodiment of the process, the device is 
maintained under tension during annealing. 
According to the invention, it is possible, in the process, to 
treat differently and separately the end-parts and median parts 
in order to have condign properties for each part. 
The device according to the invention may be used as 
ligament or tendon including elbow, shoulder, ankle, knee in 
dog, horse or human, in particular a cruciate ligament, more 
particularly an anterior cruciate ligament and may be config-
ured therefore. 
Consequently another object of the instant invention is a 
method for inserting a device comprising the following steps: 
a. providing a device according to the instant invention 
b. insertion of the device in the replacement site 
c. attaching a first end of said device to a first attachment 
site 
d. possibly, pretensioning the device 
e. attaching the second end of the device to a second attach-
ment site. 
Consequently another object of the invention is a process 
for preparing a device according to the instant invention with 
steps comprising: 
a) assembly of fibers to form the body, 
The first and the second attachment sites may be any mus-
culo-skeletal tissue to which the natural ligament or tendon is 
attached in a human or non-human animal. In case of the 
50 anterior cruciate ligament if the first attachment site is the 
femur then the second attachment site is the tibia. If the first b) impregnation of the fibers, the assembly of fibers or a 
part or the whole body of the device in a solution of 
hydro gel forming polymer or a solution of monomer or 
oligomer to coat said fibers, or said strands or said 
assembly of fibers or said body or to embed them in a 55 
hydrogel matrix, followed in the case of a solution of 
hydrogen forming monomer or oligomer by a polymer-
ization step 
c) physical or chemical cross-linking of the hydro gel coat-
ing, the hydrogel forming fibers or the hydrogel matrix 
of a part or the whole body of the device. 
In the process, the order of steps a), b) and c) may be 
modified or one of step b) and c) may be deleted. For example 
where fibers or threads or strands are coated or embedded in 
hydrogel, step b) is performed before step a). Step c) may be 
provided directly on the hydrogel forming fibers before step 
a) or step b) may be performed before step a). 
attachment site is the tibia then the second attachment site is 
the femur. 
In order to understand the invention and to see how it may 
be carried out in practice, embodiments will now be described 
by way of examples and drawings. 
FIG. 1 is a schematic drawing of one embodiment accord-
ing to the invention. About 15 hydrogel threads (1) consti-
tuted from about 12 hydrogel continuous fibers are assembled 
60 to form a strand (2). Several strands, which number is 
adjusted to impart the good mechanical properties, are 
assembled to form the body (3), about 9 to 25 strands can be 
used for replacement of a human ACL. The fiber assembly 
may be designed to have a hollow core (7). Strands may be 
65 embedded in a hydro gel matrix which is of the same nature as 
the fibers. The tibial part (5) and the femoral part (6) or both 
may be coated by a hydrogel matrix (8) differently from the 
US 9,180,000 B2 
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ligamentous part (median part) ( 4). On this particular design, 
the anchoring system (9) is a loop spliced at one end of the 
device. 
12 
To embed or coat the device, a PVA solution with the 
desired concentration (suitably in the range 5-20 wt%) was 
prepared either by dissolving the PVA fibers or by dissolving 
another PVA like PVA sold by Sigma Aldrich (suitably with 
MW of 80,000 to 186,000, 99+% hydrolyzed). These PVA 
solutions were obtained in distilled water by mixing and 
heating for about 1 hour around 90° C. 
FIG. 2 illustrates the load versus strain response during a 
tensile test for several types of device obtained following the 
invention. These results are compared to the tensile behavior 
of real ligaments and tendons as reported in the literature 
(Woo S. L. et al. American Journal of Sports Medicine, 1991, 
19, p. 217; Kim D. H. et al. American Journal of Sports 
Medicine, 2003, 31, p. 861.). 10 
In one method, fiber assemblies were mounted on a metal-
lic frame, immersed for one day at 20° C. in the solution and 
removed from the solution. In another method, they were 
encased in cylindrical moulds and the PVA solution was FIG. 3 shows the effect of annealing on the tensile behavior 
of one type of a device according to the invention. 
FIG. 4 shows the result for one type of device with and 
without coating by a hydrogel. 
FIG. 5 is relative to the measure of the flexural modulus of 
the median part. 
EXAMPLE 1 
Device Design 
Several devices have been prepared from the assembly of 
PVA fibers only, or PVA fibers and ultra-high molecular 
weight polyethylene (UHMWPE) fibers. 
PVA fibers (suitably with a dissolution temperature greater 
than 50° C. and 95+% hydrolyzed) were obtained as threads 
of more than 600 dtex composed of several continuous fibers 
like the Solvron® MH675 from Nitivy Company Ltd. PVA 
strands were prepared by winding 15 PVA threads together. 
UHMWPE fibers were obtained as threads of more than 60 
dtex like Dyneema® from DSM. 
Ten types of assembly were created with various struc-
tures, PVA/UHMWPE compositions and treatments. Fiber 
assemblies were approximately 10 mm in diameter, which is 
approximately the same diameter as the native ligament of the 
knee and currently used grafts. Geometries, compositions and 
treatments are summarized in Table 1. 
Sample Components 
Type 1 16 PVA strands 
Type 2 16 PVA strands 
Type 3 22 PVA strands 
Type4 21 PVA strands 
27UHMWPE 
threads 
Type 5 16 PVA strands 
Type 6 16 PVA strands 
Type 7 16 PVA strands 
Type 8 16 PVA strands 
Type 9 16 PVA strands 
Type 10 16 PVA strands 
TABLE 1 
Description 
16 PVA strands are assembled parallel to tbe 
direction ofloading. 
4 twisted ropes each consisting of 4 PVA 
strands twisted together. 
Central core of 4 braided PVA strands 
surrounded by 6 twisted ropes each consisting 
of 3 PVA strands twisted togetber. 
Same as Type 3 but witb 27 UHMWPE threads 
togetber as a unit substituted for one oftbe PVA 
strands in the braided central core. 
Same as Type 1 but witb annealing oftbe 
structure at 130° C. for 1 hour. 
Same as Type 1 but witb annealing oftbe 
structure at 160° C. for 1 hour. 
Same as Type 1 but witb annealing oftbe 
structure at 190° C. for 1 hour. 
Same as Type 1 but witb annealing oftbe 
structure at 160° C. for 10 min. 
Same as Type 1 but witb annealing oftbe 
structure at 190° C. for 10 min. 
Same as Type 1 but witb coating by PVA 
hydro gel using tbe immersion metbod and 
applying one freezing-tbawing cycle. 
To illustrate the effect of annealing, Type 1 assemblies 
were annealed in an oven at several temperatures and during 
different annealing times (see Types 5-9) in Table 1. In a 
preferred method, fiber assemblies are maintained under ten-
sion during annealing by clamping them on a metal frame. 
poured in these same moulds. To cross-link the hydrogel 
solution, the devices obtained by these two methods were 
thermally cycled by freezing at about -18° C. for 12 hours, 
15 and then thawing in air or distilled water by heating back to 
20° C. for 12 hours. This process represents one cycle by 
freezing-thawing. Up to 10 cycles have been applied. Cross-
linking was also performed by drying the devices at 20° C. in 
ethanol for one day and then in vacuum for one day and by 
20 rehydrating them by immersion in distilled water for one day. 
This process represents one cycle by drying-rehydrating. 
The end parts and median part of the device could be 
treated separately by these two methods. In the method by 
immersion, only the end-parts could be embedded in the PVA 
25 matrix by partially immersing the sample. In the method with 
moulds, separate moulds could be used for each end- and 
median parts. In a first step, PVA embedding was applied to 
the end-parts and followed by cross-linking and possibly 
annealing. A second PVA embedding was then applied to the 
30 median part only or to the entire device and followed by 
another cross-linking step. Different stiffnesses and proper-
ties for the median and end-parts were produced by varying 
the degree of cross-linking achieved during the first and sec-
ond steps. In one method, a solution of PVA with a dispersion 
35 ofhydroxyapatite was used to coat the end-parts only. 
40 
EXAMPLE2 
Properties of the Device 
These results correspond to the fiber assembly types pre-
sented in Table 1. 
1.1. Biocompatibility Testing 
1 H and 13C NMR analysis showed that there is no notice-
45 able distinction between the PVA used for the hydrogel form-
ing fibers and a biocompatible PVA already used for cartilage 
replacement like the one described in U.S. Pat. No. 5,981, 
826. In particular, there are no detectable traces of other 
organic compounds and PVA is hydrolyzed over 98%. For 
50 this latter PVA, biocompatibility was qualified by testing for 
ability to produce cytotoxicity, intracutaneous irritation, sen-
sitization by Kligman maximization, Ames mutagenicity, 
chromosomal aberration, and chronic toxicity. Chronic tox-
icity was assessed in combination with long-term subcutane-
55 ous implantation in a 13-week rat animal model. The material 
met the acceptance criteria for all testing conducted. 
1.2 Dimensions 
The diameter of the samples presented in Table 1 was 
measured and found in the range 10-11 mm 
60 1.3. Tensile Properties 
1.3 .1. Measurement 
Hydrogel swelling was achieved by immersing fiber 
assemblies in distilled water at 23 ° C. for 24 h prior to testing. 
Tensile testing was performed on an Instron 5966 apparatus 
65 using capstan fixations. Samples were tested less than 5 min 
after removal of water and pulled at a strain rate of about 
10-2s-l (1.5 mm s-1) which was fast enough to avoid any 
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significant drying during testing. Testing was performed at 
23° C. Instantaneous strain was measured by following ink 
marks with a video extensometer. Three samples were tested 
for each type of design as described previously in Table 1. 
1.3.2. Results 
Results are given in FIGS. 2, 3 and 4. FIG. 2 compares the 
results for type 1, 2, 3, 4, 5 and 7 with literature data showing 
the tensile behavior of native ACL and hamstring tendon 
grafts. The behavior of native ACL was reproduced from the 
results of Woo et al. (Woo S. L. et al. American Journal of 
Sports Medicine, 1991, 19, p. 217)taking a ligament length of 
20 mm to estimate strain from displacement. The behaviour 
10 
of hamstring tendon grafts was reproduced from the results of 
Kim D. H. et al. (Kim D. H. et al. American Journal of Sports 
Medicine, 2003, 31, p. 861.) taking a tendon length of30 mm 15 
to estimate strain from displacement. 
All types of device exhibited a non-linear elasticity with a 
toe region as well as an ultimate strain greater than 15% 
suitable for low tension and wear during the swing phase of 
walking. The stiffness of the devices is given by the slope of 20 
a linear fit of the load versus strain curves in the 0-10% range. 
All designs exhibited an acceptable value for stiffness within 
the range of the currently available ACL replacements. The 
Type 1 and Type 2 devices had the approximate stiffness of 
allograft replacements or the native ligament of a middle aged 
25 person. The Type 3 device had a stiffness value very close to 
that of a young person's native ACL. Finally, stiffness could 
be largely increased with the PV A/UHMWPE structure (Type 
4) or in the annealed device (Type 7). They had a stiffness up 
to about three times greater than that of native ligaments and 
similar to autografts harvested from the patellar tendon or 30 
hamstrings. In the case of the PVA/UHMWPE structure 
shown here, the high stiffness is obtained after the toe-region 
(in the 30-40% strain range). 
FIG. 3 shows how annealing can be used to tune the tensile 
behaviour. These results are obtained on a Type 1 structure but 35 
similar results are obtained on the other structures. For a given 
annealing time (1 hour), an increase in the annealing tempera-
ture from 130° C. to 190° C. increases the stiffness of the 
device up to five times (Types 5 to 7). A similar effect is 
obtained for shorter annealing times as shown with Type 9 (10 40 
min) However, a temperature that is too low and a time that is 
too short can have limited effect (Type 8). 
FIG. 4 shows the tensile behaviour for a fiber assembly 
coated by a PVA hydro gel and cross-linked with one freezing-
thawing cycle (Type 10). In this case, the mechanical 
45 
response is preserved after coating with a slight increase in 
stiffness at large deformation. 
Tensile strength was measured by dividing the load at 
break by the initial section of the sample. Here the section is 
approximated to a disk of diameter 10 mm for Types 1, 2, 5 to 
10 and 11 mm for Types 3 and 4. Ultimate tensile strain 50 
corresponds to the strain at break. All devices exhibited val-
ues ofultimate tensile load (load at break) and ultimate tensile 
strain that are appropriate for the replacement ofligaments or 
tendons. Table 2 below compares these mechanical properties 
derived from FIGS. 2, 3 and 4 with preferred values for the 55 
replacement of ACL ligaments as estimated from the litera-
ture. 
TABLE2 
14 
TABLE 2-continued 
Ultimate Tensile Ultimate 
tensile strength, tensile 
load, N MP a strain Stiffness, N/% 
Type 3 2100 22 50% 65 
Type4 4000 42 45% 30 
(150)* 
Type 5 1650 21 35% 40 
Type 6 1800 23 25% 70 
Type 7 2000 25 20% 120 
Type 8 1700 22 55% 25 
Type 9 1700 22 25% 60 
Type 10 1550 20 50% 25 
*Stiffness measured in the 30-40% strain range. 
The ligaments obtained according to the invention exhibit 
the unique combination of a tensile behaviour close to that of 
native ligaments and tendons possibly including a very simi-
lar toe-region, a tensile strength greater than 20 MPa corre-
sponding to ultimate tensile loads greater than 1500N and an 
ultimate tensile strain greater than 15% as well as the bio-
compatibility of the selected materials (PVA hydrogel and 
UHMWPE). 
EXAMPLE3 
Method of Measuring the Difference in Tensile 
Modulus Between Median and End Parts 
Tensile stiffness Sis taken as the slope of a linear fit of the 
force-strain curve in the strain range 0 to 10%. Strain is 
measured using video extensometry by following markers 
placed on the sample. It is given by (L-L0 )/L0 where L0 and L 
are the initial and instantaneous distances between markers, 
respectively. 
All measurements are made in a swollen state: samples are 
immerged in distilled water for over 12 h prior to testing and 
are tested less than 5 min after removal from water and pulled 
at a strain rate of about 10-2 s- 1 (1.5 mm s- 1 ). 
Examples of Manufacturing Processes 
For devices wherein the tensile stiffness of the end parts is 
at least twice as much as that of the median part (Send par! 
smedian>2) the fabrication process consists in coating or 
embedding the ends of a PVA construct made of one PVA 
bundle composed of! 5 twisted PVA threads themselves com-
posed of 15 twisted fibers with a 15 wt % PVA aqueous 
solution by dipping and physically cross-linking the solution 
by drying. 
Results as follows: 
With no treatment Smedian =0.4N/% 
With coating+drying treatment 
smedian 
Send part=l .4N/%>2 
For devices wherein the tensile stiffness of the end parts is 
at least five times as much as that of the median part 
(Send par/Smedian>5) the fabrication process consists in coat-
ing or embedding the end parts of a PVA construct made of 
Ultimate Tensile 
tensile strength, 
load,N MP a 
Preferred values for 1100- 15-50 
ACL replacement 4000 
Ultimate 
tensile 
strain 
>15% 
Stiffness, N/% 
20 (nativeACL) 
300 (tendon) 
60 one PVA bundle composed of 15 twisted PVA threads them-
selves composed of 15 twisted fibers with a 15 wt% PVA 
aqueous solution by dipping and physically cross-linking the 
solution by drying followed by local annealing at 150° C. for 
1 h. 
Type 1 1700 22 65% 
Type 2 1750 22 60% 
25 65 
40 
With no treatment Smedian =0.4N/% 
With coating+drying+annealing treatment 
6N/%>5 Smedian 
part 
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In order to obtain devices having a different ratio between 
the tensile modulus of the end parts and that of the median 
part, other fabrication processes may include the addition of 
biomineral fillers such as hydroxyapatite to in the hydrogel 
matrix embedding or coating the end parts, or local annealing 
of end parts only. 
EXAMPLE4 
Method of Measuring the Tensile Behaviour of the 
Median Part in the Low (0 to 5%) Strain Regime 
10 
16 
Alternative fabrication processes include the assembly in 
different appropriate proportions of parallel PVA fibers (in 
the form of fibers, threads or strands) and high modulus fibers 
such as UHMWPE, silk, Kevlar, PET, polyester 
EXAMPLE 5 
Method of Measuring the Tensile Behaviour of the 
Median Part in the Larger (10 to 15%) Strain Regime 
Method: 
Same method as for the low strain regime. Here modulus 
E10_15 is taken as the slope of a linear fit of the stress-strain 
curve in the strain range 10 to 15%. 
Examples of Manufacturing Processes: 
Fabrication process for devices having a tensile modulus 
superior to 1 or 10 MPa in the 10 to 15% strain range. 
Modulus (E0 _5 ) is taken as the slope of a linear fit of the 
stress-strain curve in the strain range 0 to 5%. Stress is cal-
culated by dividing the tensile force by the initial cross- 15 
section area of the median part, S0 . Strain is measured using 
video extensometry by following markers placed on the 
sample. It is given by (L-L0)/L0 where L0 and Lare the initial 
and instantaneous distances between markers, respectively. 
The fabrication process consists in assembling PVA 
strands in parallel. Each strand being composed of PVA 
threads, in tum composed of twisted PVA fibers. PVA threads 
20 are Solvron® MH675 provided by Nitivy Company Ltd. and 
have more than 600 dtex. 
All measurements are made in a swollen state: samples are 
immerged in distilled water for over 12 h prior to testing and 
are tested less than 5 min after removal from water and pulled 
at a strain rate of about 10-2 s- 1 (1.5 mm s- 1 ). 
Examples of Manufacturing Processes: 
Fabrication process for devices having a tensile modulus 25 
superior to 1 or 10 MPa in the 0 to 5% strain range. 
The process consists in assembling PVA strands in parallel. 
Each strand being composed of PVA threads, in tum com-
posed of twisted PVA fibers. PVA threads are Solvron® 
MH675 provided by Nitivy Company Ltd. and have more 30 
than 600 dtex. Typical median part is composed of 16 parallel 
PVA strands. 
Diameter: 9.5 mm 
Cross-Section area: 71 mm2 
Tensile modulus in the 0-5% strain range is: 20 MPa 
Another fabrication process consists in an assembly of a 
central core composed of PVA strands to form an outside 
structure wrapping a central core composed of braided PVA 
and UHMWPE strands. 
Diameter: 10 mm 
Cross-Section area: 78 mm2 
Tensile modulus in the 0-5% strain range is: 27 MPa 
Fabrication process for devices having a tensile modulus 
35 
40 
Typical median part is composed of 16 parallel PVA 
strands. 
Diameter: 9.5 mm 
Cross-Section area: 71 mm2 
Tensile modulus in the 10-15% strain range is: 30 MPa 
Fabrication process for devices having a tensile modulus 
superior to 40 MPa in the 10 to 15% strain range. 
The fabrication process consists in an assembly of a central 
core composed of PVA strands to form an outside structure 
wrapping a central core composed of braided PVA and UHM-
WPE strands. 
Diameter: 10 mm 
Cross-Section area: 78 mm2 
Tensile modulus in the 10-15% strain range is: 47 MPa 
Another fabrication process consists in assembling 16 par-
allel PVA strands in parallel like described above and achiev-
ing an annealing of 130° C. for 1 h under tension. 
Diameter: 8.5 mm 
Cross-Section area: 57 mm2 
Tensile modulus in the 10-15% strain range is: 89 MPa 
Fabrication process for devices having a tensile modulus 
superior to 100 MPa in the 10 to 15% strain range. 
superior to 40 MPa in the 0 to 5% strain range. 
The fabrication process consists in assembling PVA 
strands in parallel like indicated above and achieving an 
annealing of 130° C. for 1 h under tension. Typical median 
part is composed of 16 parallel PVA strands. 
Same process as above with annealing at higher tempera-
45 ture: 160° C. for 1 h. The median part consists in 16PVA 
Diameter: 8.5 mm 
Cross-Section area: 57 mm2 
Tensile modulus in the 0-5% strain range is: 68 MPa 
Fabrication process for devices having a tensile modulus 
superior to 100 MPa in the 0 to 5% strain range. 
50 
Same process as above with annealing at higher tempera-
ture: 160° C. for 1 h. As above, the median part consists in 55 
16PVA strands in parallel. 
Diameter: 8.2 mm. 
Cross-Section area: 53 mm2 
Tensile modulus in the 0-5% strain range is: 126 MPa 
Fabrication process for devices having a tensile modulus 60 
superior to 150 MPa in the 0 to 5% strain range. 
strands in parallel 
Diameter: 8.2 mm. 
Cross-Section area: 53 mm2 
Tensile modulus in the 10-15% strain range is: 152 MPa 
Fabrication process for devices having a tensile modulus 
superior to 150 MPa in the 10 to 15% strain range. 
Same process as above with annealing at higher tempera-
ture: 190° C. for 1 h. As above, median part consists in 16PVA 
strands in parallel 
Diameter: 8.5 mm 
Cross-Section area: 57 mm2 
Tensile modulus in the 10-15% strain range is: 191 MPa 
EXAMPLE 6 
Method of Measuring the Flexural Modulus of the 
Median Part Same process as above with annealing at higher tempera-
ture: 190° C. for 1 h. As above, the median part consists in 
16PVA strands in parallel. 
Diameter: 8.5 mm 
Cross-Section area: 57 mm2 
Flexural modulus Efis measured by performing a 3 point-
65 bending test under constant load P (attaching a weight in the 
middle of the sample), and measuring the corresponding 
Tensile modulus in the 0-5% strain range is: 174 MPa deflection d. 
US 9,180,000 B2 
17 
Efis then given by: 
E;=(L3!481Gz)*(P!d) 
where IGz =b·h3 /12 for a rectangular cross-section of height h 
and width b. 
or IGz =it·D4/64 for a circular cross-section of diameter D. 
See FIG. 5. 
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15. The device according to claim 6, wherein the end parts 
are coated or impregnated with one or several osseointegra-
tion-promoting substances. 
16. The device according to claim 1, wherein the hydrogel 
forming fibers are made of polyvinyl alcohol. 
17. The device according to claim 1, wherein the hydrogel 
forming fibers are made of polyvinyl alcohol having a water 
absorption higher than 10% in weight. For braided structures of 12 PVA strands, diameters D of 
about 8 mm are obtained and the measured flexural modulus 
is about 15-30 MPa. 10 
18. The device according to claim 1, further comprising 
other types ofbiocompatible fibers assembled with the hydro-
gel forming fibers. 
A fabrication process forthe median part consists in assem-
bling 12 PVA strands in parallel or in a twisted structure. For 
this case, diameter is D=S mm and measured flexural modu-
lus is about 8 MPa. 
19. The device according to claim 18, further comprising 
biocompatible fibers selected from the group consisting of 
Another fabrication process consists in making a hollow 
device, using for instance assembly around rod that is 
removed after assembly. For this type of structure, using 12 
twisted PVA strands, diameter is D=S mm and measured 
flexural modulus is about 3 MPa. 
15 Polyethylene (PE), Poly-L-lactic acid (PLLA), Poly-G-lactic 
acid (PGLA), Poly-caprolactone (PCL), Silk, Polyesters, 
Polyethylene terephtalate (PET), Polytetrafluoroethylene 
(PTFE), PLGA, and Ti wires fibers assembled with the hydro-
The invention claimed is: 20 
1. A biocompatible device in the form of an elongated body 
comprising a flexible median part between two end parts 
showing a different tensile stiffness from that of the median 
part, said body having a fibrous structure formed from bio-
compatible hydrogel forming fibers, said hydrogel forming 25 
fibers forming the body of the device, wherein the body is 
partly or totally coated or entrapped in a hydrogel matrix. 
gel forming fibers. 
20. The device according to claim 1, further comprising at 
least at one end part an anchoring system selected from the 
group consisting of a hook, a screw, a buckle, a bone anchor, 
an interference screw, a cross pin, a suture button, and an eye 
spliced at said end. 
21. The device according to claim 1, wherein at least one of 
the end parts is filled with a substance, selected from the 
group consisting of bone mulch, bone cement, and a mineral 
filler. 2. The device according to claim 1, wherein the two end parts show a higher tensile stiffness than that of the flexible 
median part. 22. The device according to claim 1, wherein the hydrogel 30 forming fibers forming the body of the device can be cross-3. The device according to claim 1, wherein the two end 
parts show a higher bending stiffness than that of the flexible 
median part. 
4. The device according to claim 1, wherein the median part 
shows an ultimate tensile strain greater than 6%. 35 
5. The device according to claim 1, wherein the two end 
parts show a tensile stiffness that is from 10% to 100 times 
higher, than that of the flexible median part. 
6. The device according to claim 1, wherein the end parts 
are placed adjacently to each of the ends of the median part 40 
and are made of swellable and porous braided, twisted, woven 
or knitted sections. 
7. The device according to claim 1, wherein the flexible 
median part has a nonlinear elasticity. 
8. The device according to claim 1, wherein the median part 45 
whose tension stress-strain curve shows a low stiffness region 
at the lowest levels of tensile strain and a higher stiffness 
region at greater levels of strain. 
linked. 
23. A process for preparing a device according to claim 1 
comprising the following steps: 
a) assembly of fibers to form the body, 
b) impregnation ofimpregnating the fibers, the assembly of 
fibers or a part or the whole body of the device in a 
solution ofhydrogel-forming polymer or a solution of 
monomer or oligomer to coat said fibers, or said strands 
or said assembly of fibers or said body or to embed them 
in a hydrogel matrix, followed in the case of a wherein 
impregnating with the solution of monomer or oligomer 
being followed by a polymerization step, 
c) physical or chemical cross-linking the hydro gel coating, 
the hydro gel forming fibers or the hydrogel matrix of a 
part or the whole body of the device. 
24. The process according to claim 23 wherein the hydro-
gel-forming polymer is polyvinyl alcohol and polyvinyl alco-
hol fibers are used step c) comprises a physical cross-linking 9. The device according to claim 1, wherein the flexible 
median part shows in the 0 to 5% strain range a tensile 
modulus of 1 to 500 MPa. 
10. The device according to claim 1, wherein the flexible 
median part shows in a 10 to 15% strain range a tensile 
modulus 1 to 500 MPa. 
50 
step selected from a series of freezing/thawing cycles and/or 
drying/rehydrating cycles and/or a chemical cross-linking 
step preferably using irradiation and/or a dialdehyde cross-
linker preferably glutaraldehyde. 
11. The device according to claim 1, wherein the median 
part shows in a 10 to 15% strain range a tensile stiffness 
comprised from about 10 to 500 N/%. 
25. The process according to claim 23 further comprising 
55 
an annealing step at a temperature near the melting point of 
the hydro gel forming fibers, before or after step c) of a part or 
the whole body of the device. 
12. The device according to claim 1, wherein the median 
part shows a flexural modulus from 0.1 to 200 MPa. 
13. The device according to claim 1, wherein the fibers and 60 
or threads are continuous. 
14. The device according to claim 1, wherein the end parts 
are made of tubular braided, twisted, woven or knitted sec-
tions that contain at least one osseointegration promoting 
substance and/or the device has holes at each end of a tubular 65 
section or on a side of the tubular section to allow injection of 
materials into the space inside the tubular section. 
26. A method for inserting a device comprising the follow-
ing steps: 
a) providing a device according to claim 1, 
b) inserting the device in he a replacement site 
c) attaching a first end part of said device to a first attach-
ment site 
d) optionally, pretensioning the device 
e) attaching a second end part of the device to a second 
attachment site. 
* * * * * 
